Follistatin 344 1mg

$175.00

+ Free Shipping

Follistatin 344 is a recombinant, full-length protein analogue of human follistatin (FST) that is studied as a high-affinity binding protein for select TGF-β superfamily ligands, including activins and myostatin. Follistatin-344 protein research commonly focuses on how ligand sequestration alters downstream signaling networks that regulate cellular proliferation, differentiation, and tissue remodeling under controlled laboratory conditions. As a precursor-length construct, it is also used in experimental settings to examine isoform processing and the functional differences between full-length and shorter follistatin variants.

In vitro assays and animal models have evaluated endpoints such as SMAD pathway activity, transcriptional changes in activin/myostatin-responsive genes, markers of myogenesis and extracellular matrix remodeling, and cytokine-associated signaling readouts relative to controls. Major research areas include skeletal muscle signaling models, activin-regulated developmental and endocrine biology studies, and mechanistic investigations of inflammation- and fibrosis-associated pathways. These systems are central to laboratory research because they help characterize how extracellular ligand availability can shift cell-state decisions and tissue-level phenotypes in preclinical models.

For research use only. Not for human consumption.

References:
Lee SJ et al., Proc Natl Acad Sci USA, 2001 98(16):9306–9311
Cash JN et al., J Biol Chem, 2009 284(13):9011–9020
Sidis Y et al., Endocr Rev, 2001 22(5):726–729

SKU: 2AKnb5aj3v Category:
Guaranteed Safe Checkout

Ligand Sequestration Studies in Myostatin/Activin Signaling Models

Animal and cellular studies have used follistatin-based approaches (including protein, mRNA, and gene-expression systems) to evaluate the consequences of myostatin/activin pathway inhibition on molecular markers, tissue morphology, and functional readouts in controlled experimental designs[1], [3], [4], [5].

Strength-related readouts reported in follistatin-associated experimental paradigms.Strength-related readouts reported in follistatin-associated experimental paradigms.
Source:

Oncology Model Context (Expression and Mechanistic Associations)

Preclinical investigations and molecular profiling studies have examined follistatin expression in tumor-associated contexts and evaluated mechanistic associations with activin-related signaling, migration, and metastatic behavior in defined experimental systems, including mouse models[6], [7], [8], [9].

Recurrence-associated probability curves in breast cancer datasets stratified by follistatin (FST) expression.Recurrence-associated probability curves in breast cancer datasets stratified by follistatin (FST) expression.

Cell Proliferation, Fibrosis Markers, and Liver Model Systems

Mechanistic research in hepatocyte and hepatic stellate cell biology has examined the activin–follistatin axis in relation to proliferation-associated behavior, apoptosis markers, and fibrosis-related endpoints in controlled animal and cell-based models.

Developmental Biology and BMP/TGF-β Signaling Context

Developmental model studies have evaluated TGF-β and BMP signaling dynamics in processes such as optic fissure fusion, providing context for investigating how pathway antagonism and related modulators influence morphogenesis-associated signaling outcomes in model systems

Metabolic and Endocrine Pathway Investigations in Animal Models

Preclinical studies have evaluated forced expression of follistatin in defined animal model systems to assess pathway-regulated molecular and physiological endpoints, including pancreatic β-cell biology and glycemic measurements, under controlled experimental conditions

Note: Citations may include a mixture of preclinical reports and broader pathway reviews. Any cited clinical material is provided solely as bibliographic context and should not be interpreted as suggesting clinical, diagnostic, or therapeutic use.

Follistatin 344 1mgFollistatin 344 1mg
$175.00